Ironwood Pharmaceuticals, Inc. (IRWD) – Aktiekurs og nyheder

Symboler Symboler	Pris	Ændring	Ændring i %	Tendens	Forrige slutpris	Åbn	Høj	Lav	Volumen	Kursværdi
SIXB Materials SIXB Materials	SIXB +0,25%	1.104,10	+2,73	+0,25%	—	1.101,37	1.103,63	1.105,31	1.091,41	—	—
SIXC Communications SIXC Communications	SIXC -1,50%	604,16	-9,19	-1,50%	—	613,35	613,35	613,35	601,49	—	—
SIXE Energy SIXE Energy	SIXE -0,09%	1.197,81	-1,02	-0,09%	—	1.198,83	1.199,68	1.199,75	1.182,41	—	—
SIXI Industrials SIXI Industrials	SIXI -0,88%	1.740,41	-15,54	-0,88%	—	1.755,95	1.754,06	1.756,03	1.734,69	—	—
SIXM Financials SIXM Financials	SIXM -0,64%	634,44	-4,07	-0,64%	—	638,51	637,41	637,41	633,05	—	—
SIXR Staples SIXR Staples	SIXR -0,31%	840,90	-2,62	-0,31%	—	843,52	843,35	846,40	837,93	—	—
SIXRE Real estate SIXRE Real estate	SIXRE -0,38%	215,13	-0,82	-0,38%	—	215,95	215,95	216,84	215,06	—	—
SIXT Technology SIXT Technology	SIXT +2,86%	3.228,71	+89,80	+2,86%	—	3.138,91	3.189,30	3.230,85	3.174,76	—	—
SIXU Utilities SIXU Utilities	SIXU +0,16%	935,87	+1,50	+0,16%	—	934,37	934,72	938,26	927,50	—	—
SIXV Health care SIXV Health care	SIXV -1,37%	1.457,12	-20,31	-1,37%	—	1.477,43	1.474,12	1.474,12	1.451,80	—	—
SIXY Discretionary SIXY Discretionary	SIXY +0,83%	2.399,84	+19,65	+0,83%	—	2.380,19	2.389,34	2.403,04	2.380,47	—	—

IRWD:NASDAQ

Ironwood Pharmaceuticals, Inc.

3,93 US$

+3,69%

(+0,14) 1D

3,90 US$

-0,76% (-0,030)

Eftermarked

Lukket: 24. apr., 16.00.01 GMT-4 · USD

Alle symboler

ÅTD

1Å

5Å

MAKS

	Symbol	Pris	Ændring	Ændring i %

Genererer vigtig indsigt for IRWD...

Åbn

3,79 US$

Høj

3,93 US$

Lav

3,72 US$

Markedsværdi

640,82 mio.

Gns. vol.

2,61 mio.

Volumen

1,32 mio.

P/E-forhold

26,67

Højeste i 52 uger

5,78 US$

Laveste i 52 uger

0,53 US$

Indtægt pr. aktie

0,15 US$

Beta

0,17

Aktier i omløb

163,06 mio.

Antal ansatte

100

Relaterede aktier

BCRX

BioCryst Pharmaceuticals Inc

8,94 US$

+2,05%

BNAI

Brand Engagement Network Inc

30,02 US$

-4,09%

CTMX

CytomX Therapeutics Inc

4,40 US$

-1,12%

RLAY

Relay Therapeutics Inc

15,13 US$

+0,27%

Nyhedshistorier

Fra kilder på hele internettet

Yahoo Finance

for 2 dage siden

Ironwood Pharmaceuticals to Share Real-World HCP Perspectives on Burden of Total Parenteral Nutrition in Short Bowel Syndrome (SBS) at Digestive Disease Week® 2026

Profil

Ironwood Pharmaceuticals, Inc. is a publicly traded pharmaceutical company. It was originally called Microbia, Inc. Microbia was founded by postdocs from the lab of Gerald Fink at the Whitehead Institute to commercialize approaches that had been developed in the lab to improve industrial fermentation of fungi, to genetically engineer them to produce secondary metabolites more efficiently or to produce new ones as leads for drug discovery or as products for use in industry, and to identify drug targets in fungi for antifungal drug discovery. In 2002 the company hired John Talley to lead their antifungal drug discovery efforts, which at the time were focused on identifying small molecules that could inhibit fungal invasins, along with Mark Currie who had also worked at Searle division of Monsanto with Talley, and then had gone to Sepracor, and also Richard Bailey, who had run Monsanto's nutritional business. Currie directed the efforts that led to the discovery of linaclotide, which was based on an enterotoxin produced by some strains of Escherichia coli that cause traveler’s diarrhea. By 2004 the company had raised $99M and was preparing a Phase I trial for linaclotide. Wikipedia

Om Ironwood Pharmaceuticals, Inc.

Administrerende direktør-

Ansatte100

Grundlagt1998

HovedsædeBoston, Massachusetts, USA

Sektor-

Websiteironwoodpharma.com

Alle værdier i USD	mar. 2025	jun. 2025	sep. 2025	dec. 2025
Omsætning	41,14 mio.	85,24 mio.	122,06 mio.	47,71 mio.
Varens egenpris	27,43 mio.	23,37 mio.	22,47 mio.	21,86 mio.
Direkte omkostninger forbundet med produkter og tjenester	27,43 mio.	23,37 mio.	22,47 mio.	21,86 mio.
Udgifter til forskning og udvikling	-	-	-	-
Samlede udgifter til forskning og udvikling	-	-	-	-
Salgsrelaterede, generelle og administrative udgifter	24,26 mio.	16,80 mio.	21,91 mio.	19,29 mio.
Driftsomkostninger	24,26 mio.	16,80 mio.	21,91 mio.	19,29 mio.
Samlede driftsomkostninger	51,69 mio.	40,17 mio.	44,38 mio.	41,16 mio.
Driftsindtægt	-10,55 mio.	45,07 mio.	77,68 mio.	6,55 mio.
Anden øvrig driftsindtægt	37,00 t	39,00 t	40,00 t	77,00 t
Indtjening før skat, inkl. usædvanlige varer	-36,27 mio.	37,82 mio.	68,02 mio.	455,00 t
Indtjening før skat, ekskl. usædvanlige varer	-17,71 mio.	37,57 mio.	70,22 mio.	203,00 t
Indkomstskat	1,11 mio.	14,22 mio.	27,94 mio.	2,73 mio.
Effektiv skattesats	-3,07 %	37,60 %	41,08 %	600,22 %
Andre driftsudgifter	-	-	-	-
Nettoindtægt	-37,39 mio.	23,60 mio.	40,08 mio.	-2,28 mio.
Nettooverskudsgrad	-90,87 %	27,69 %	32,84 %	-4,77 %
Indtægt pr. aktie	-0,14	0,14	0,24	-0,01
Renter og investeringsindtægt	869,00 t	818,00 t	930,00 t	1,46 mio.
Renteudgift	-8,07 mio.	-8,36 mio.	-8,43 mio.	-7,89 mio.
Renteudgifter (netto)	-7,20 mio.	-7,54 mio.	-7,50 mio.	-6,43 mio.
Afskrivnings- og amortiseringsgebyrer	-	-	-	-
EBITDA	-10,07 mio.	45,54 mio.	78,16 mio.	7,01 mio.
Fortjeneste eller tab ved salg af aktiver	-	85,00 t	7,00 t	-3,00 t

AI-indhold kan indeholde fejl. Få flere oplysninger

HjælpSend feedbackPrivatliv Vilkår Ansvarsfraskrivelse

Finans

Undersøg